Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates

Journal of Thrombosis and Haemostasis · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles